Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology

Jonathan Richard White; Krish Ragunath; Aimee Whitton; Elizabeth Marsh; Philip Kaye; Gillian Knight

doi:10.1136/bmjgast-2021-000840

Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology

Jonathan Richard White, Krish Ragunath, Aimee Whitton, Elizabeth Marsh, Philip Kaye, Gillian Knight

Chemical Engineering & Applied Chemistry

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study applies a novel HPV screening tool (previously only used in the oropharynx) to detect HPV DNA directly and determine the prevalence rates in Barrett's oesophagus (BO). Method DNA was extracted from 20 formalin-fixed BO samples. HPV DNA was detected using real-time PCR and gel electrophoresis. Results 5 out of 20 patients were identified as positive for HPV. Prevalence was 25% in patients with BO. Conclusion This method can be used in BO's tissue to determine HPV infection. Adoption of this as a screening test could potentially revolutionise future research in this area. If a clear link between HPV and Barrett's dysplasia can be confirmed, this qPCR method has the potential to aid in monitoring and/or dysplasia detection by stratifying those most at risk and aid in the development of new therapies.

Original language	English
Article number	e000840
Journal	BMJ open gastroenterology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1136/bmjgast-2021-000840
Publication status	Published - 4 Apr 2022

Bibliographical note

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Keywords

Barrett Esophagus - diagnosis - epidemiology
Barrett's oesophagus
polymerase chain reaction
Prevalence
Alphapapillomavirus
Humans
Papillomaviridae - genetics
Pilot Projects
oesophageal cancer
Papillomaviridae/genetics
Barrett Esophagus/diagnosis

Access to Document

10.1136/bmjgast-2021-000840Licence: CC BY-NC 4.0

Study to investigate the prevalence of human papillomavirus
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Final published version, 581 KBLicence: CC BY-NC 4.0

Cite this

@article{74e45658af724321b08edf60b8a35bd1,

title = "Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology",

abstract = "Introduction Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study applies a novel HPV screening tool (previously only used in the oropharynx) to detect HPV DNA directly and determine the prevalence rates in Barrett's oesophagus (BO). Method DNA was extracted from 20 formalin-fixed BO samples. HPV DNA was detected using real-time PCR and gel electrophoresis. Results 5 out of 20 patients were identified as positive for HPV. Prevalence was 25% in patients with BO. Conclusion This method can be used in BO's tissue to determine HPV infection. Adoption of this as a screening test could potentially revolutionise future research in this area. If a clear link between HPV and Barrett's dysplasia can be confirmed, this qPCR method has the potential to aid in monitoring and/or dysplasia detection by stratifying those most at risk and aid in the development of new therapies.",

keywords = "Barrett Esophagus - diagnosis - epidemiology, Barrett's oesophagus, polymerase chain reaction, Prevalence, Alphapapillomavirus, Humans, Papillomaviridae - genetics, Pilot Projects, oesophageal cancer, Papillomaviridae/genetics, Barrett Esophagus/diagnosis",

author = "White, {Jonathan Richard} and Krish Ragunath and Aimee Whitton and Elizabeth Marsh and Philip Kaye and Gillian Knight",

note = "{\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. ",

year = "2022",

month = apr,

day = "4",

doi = "10.1136/bmjgast-2021-000840",

language = "English",

volume = "9",

number = "1",

}

TY - JOUR

T1 - Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology

AU - White, Jonathan Richard

AU - Ragunath, Krish

AU - Whitton, Aimee

AU - Marsh, Elizabeth

AU - Kaye, Philip

AU - Knight, Gillian

N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PY - 2022/4/4

Y1 - 2022/4/4

N2 - Introduction Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study applies a novel HPV screening tool (previously only used in the oropharynx) to detect HPV DNA directly and determine the prevalence rates in Barrett's oesophagus (BO). Method DNA was extracted from 20 formalin-fixed BO samples. HPV DNA was detected using real-time PCR and gel electrophoresis. Results 5 out of 20 patients were identified as positive for HPV. Prevalence was 25% in patients with BO. Conclusion This method can be used in BO's tissue to determine HPV infection. Adoption of this as a screening test could potentially revolutionise future research in this area. If a clear link between HPV and Barrett's dysplasia can be confirmed, this qPCR method has the potential to aid in monitoring and/or dysplasia detection by stratifying those most at risk and aid in the development of new therapies.

AB - Introduction Human papillomavirus (HPV) is strongly associated with Barrett's dysplasia and oesophageal cancer suggesting a role in carcinogenesis. HPV persistence predicts treatment failure after endotherapy for Barrett's dysplasia. This pilot study applies a novel HPV screening tool (previously only used in the oropharynx) to detect HPV DNA directly and determine the prevalence rates in Barrett's oesophagus (BO). Method DNA was extracted from 20 formalin-fixed BO samples. HPV DNA was detected using real-time PCR and gel electrophoresis. Results 5 out of 20 patients were identified as positive for HPV. Prevalence was 25% in patients with BO. Conclusion This method can be used in BO's tissue to determine HPV infection. Adoption of this as a screening test could potentially revolutionise future research in this area. If a clear link between HPV and Barrett's dysplasia can be confirmed, this qPCR method has the potential to aid in monitoring and/or dysplasia detection by stratifying those most at risk and aid in the development of new therapies.

KW - Barrett Esophagus - diagnosis - epidemiology

KW - Barrett's oesophagus

KW - polymerase chain reaction

KW - Prevalence

KW - Alphapapillomavirus

KW - Humans

KW - Papillomaviridae - genetics

KW - Pilot Projects

KW - oesophageal cancer

KW - Papillomaviridae/genetics

KW - Barrett Esophagus/diagnosis

UR - https://bmjopengastro.bmj.com/content/9/1/e000840.info

UR - http://www.scopus.com/inward/record.url?scp=85128405209&partnerID=8YFLogxK

U2 - 10.1136/bmjgast-2021-000840

DO - 10.1136/bmjgast-2021-000840

M3 - Article

C2 - 35379652

SN - 2054-4774

VL - 9

JO - BMJ open gastroenterology

JF - BMJ open gastroenterology

IS - 1

M1 - e000840

ER -

Study to investigate the prevalence of human papillomavirus in Barrett's oesophagus using a novel screening methodology

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this